At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback